LILRB1/CD85j/ILT2, His & Avi, Human
¥2200 | |
Z05593-100 | |
|
|
|
|
|
¥2200 | |
Z05593-100 | |
|
|
|
|
|
Species | Human | ||||||
Protein Construction |
|
||||||
Purity | > 95% as determined by BisTris PAGE | ||||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
Expression System | HEK293 | ||||||
Theoretical Molecular Weight | 50 kDa | ||||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 72-78 kDa based on Bis-Tris PAGE result. | ||||||
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Serial dilutions of LILRB1/CD85j/ILT2, His & Avi, Human Antibody were added into Biotinylated Human HLA-G Complex Tetramer, His Tag : Human LILRB1, His Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 27ng/ml. »
Immobilized LILRB1/CD85j/ILT2, His & Avi, Human, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB1 Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA. »
The purity of LILRB1/CD85j/ILT2, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
LILRB1/CD85j/ILT2, His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%. »
Target Background | LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. |
Synonyms | ILT2; ILT-2; ILT2FLJ37515; LILRB1; LIR1; MIR7; CD85J; XXbac-BCX85G21.4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.